POU2F2

Across TCGA pan-cancer cohorts, POU2F2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated POU2F2 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher POU2F2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POU2F2 expression acts as an unfavorable survival marker.

LUSC, KICH, and HNSC are the cancer types where POU2F2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.242	0.735	.002	24	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
HNSC	DFS	Median	II,III,IV	0.170	0.662	.016	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

POU2F2–LUSC (OS)

Open the LUSC breakdown →